FDA Approves Kebilidi for Aromatic L-Amino Acid Decarboxylase Deficiency
By Lori Solomon HealthDay Reporter
TUESDAY, Nov. 26, 2024 -- The U.S. Food and Drug Administration has approved Kebilidi (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.
The adeno-associated virus vector-based gene therapy is the first FDA-approved gene therapy for treatment of AADC deficiency, a rare genetic disorder affecting the production of some neurotransmitters. Kebilidi needs to be administered in a medical center that specializes in pediatric stereotactic neurosurgery. In one surgical session, four infusions are delivered to the brain region involved in motor control.
The accelerated approval was based on an open-label, single-arm clinical study that included 13 pediatric patients with a confirmed diagnosis of AADC deficiency. At baseline, all patients had no gross motor function (the most severe presentation of AADC deficiency) and decreased AADC activity in the plasma. Compared with untreated patients (natural history), eight of 12 patients treated with Kebilidi exhibited improvement in gross motor function at week 48.
"Clinical advancements in the field of gene therapy continue to lead to the discovery and availability of innovative treatment options for rare diseases that are otherwise difficult to manage," Peter Marks, M.D., Ph.D., from the FDA Center for Biologics Evaluation and Research, said in a statement.
Approval of Kebilidi was granted to PTC Therapeutics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Swept-Source Anterior Segment OCT Can Help Distinguish Early Childhood Glaucoma
FRIDAY, May 23, 2025 -- The noninvasive swept-source anterior-segment optical coherence tomography (SS-ASOCT) can diagnose early-onset childhood glaucoma, according to a study...
Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss
FRIDAY, May 23, 2025 -- Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in...
Higher Social Media Use Tied to Subsequent Depressive Symptoms in Youth
FRIDAY, May 23, 2025 -- Higher social media use is associated with greater subsequent depressive symptoms in children and adolescents, according to a study published online May 21...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.